论文部分内容阅读
目的:比较培美曲塞联合顺铂与多西他赛联合顺铂二线治疗晚期肺腺癌的临床效果。方法:筛选从2012年5月到2014年3月在我院就诊的肺腺癌患者,将符合入组标准的80例晚期肺腺癌患者随机分为实验组与对照组,每组均为40例,实验组用培美曲塞联合顺铂的方法治疗,对照组用多西他赛联合顺铂的方法治疗。对两组的治疗效果进行统计分析。结果:治疗后发现实验组的总有效率为42.5%,对照组的总有效率为35%,两组相比差异无统计学意义,P>0.05。实验组的毒副发生率低于对照组,差异有统计学意义,P<0.05。结论:培美曲塞联合顺铂二线治疗肺腺癌临床疗效与多西他赛联合顺铂二线治疗晚期肺腺癌的临床疗效相当,但毒副反应发生率较低。
Objective: To compare the clinical efficacy of pemetrexed combined with cisplatin and docetaxel plus cisplatin in the treatment of advanced lung adenocarcinoma. Methods: A total of 80 patients with advanced adenocarcinoma of lung adenocarcinoma who met the criteria of admission were randomly divided into experimental group and control group, with each group being 40 For example, the experimental group with pemetrexed combined with cisplatin treatment, the control group with docetaxel combined with cisplatin treatment. The two groups of treatment were statistically analyzed. Results: After treatment, the total effective rate was 42.5% in the experimental group and 35% in the control group. There was no significant difference between the two groups (P> 0.05). The incidence of poisoning in the experimental group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical efficacy of pemetrexed combined with cisplatin in the treatment of lung adenocarcinoma is comparable to that of docetaxel combined with cisplatin in the treatment of advanced lung adenocarcinoma. However, the incidence of toxic and side effects is low.